530 related articles for article (PubMed ID: 20578100)
1. Management of residual shunts after initial percutaneous patent foramen ovale closure: a single center experience with immediate and long-term follow-up.
Diaz T; Cubeddu RJ; Rengifo-Moreno PA; Cruz-Gonzalez I; Solis-Martin J; Buonanno FS; Inglessis I; Palacios IF
Catheter Cardiovasc Interv; 2010 Jul; 76(1):145-50. PubMed ID: 20578100
[TBL] [Abstract][Full Text] [Related]
2. Residual shunting after percutaneous PFO closure: how to manage and how to close.
Butera G; Sarabia JF; Saracino A; Chessa M; Piazza L; Carminati M
Catheter Cardiovasc Interv; 2013 Nov; 82(6):950-8. PubMed ID: 23804551
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
[TBL] [Abstract][Full Text] [Related]
4. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
5. Residual shunt after percutaneous closure of patent foramen ovale with AMPLATZER occluder devices - influence of anatomic features: a transcranial Doppler and intracardiac echocardiography study.
Marchese N; Pacilli MA; Inchingolo V; Fanelli R; Loperfido F; Vigna C
EuroIntervention; 2013 Jul; 9(3):382-8. PubMed ID: 23872652
[TBL] [Abstract][Full Text] [Related]
6. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study.
Paciaroni M; Agnelli G; Bertolini A; Pezzini A; Padovani A; Caso V; Venti M; Alberti A; Palmiero RA; Cerrato P; Silvestrelli G; Lanari A; Previdi P; Corea F; Balducci A; Ferri R; Falcinelli F; Filippucci E; Chiocchi P; Grandi FC; Ferigo L; Musolino R; Bersano A; Ghione I; Sacco S; Carolei A; Baldi A; Ageno W;
Cerebrovasc Dis; 2011; 31(2):109-16. PubMed ID: 21088390
[TBL] [Abstract][Full Text] [Related]
7. Recurrent events after percutaneous closure of patent foramen ovale.
Wallenborn J; Bertog SC; Franke J; Steinberg DH; Majunke N; Wilson N; Wunderlich N; Sievert H
Catheter Cardiovasc Interv; 2013 Oct; 82(4):541-6. PubMed ID: 22707325
[TBL] [Abstract][Full Text] [Related]
8. Initial experience with the novel patent foramen ovale occlusion device Nit-Occlud® in patients with stroke or transient ischemic attack.
Steinberg DH; Bertog SC; Momberger J; Franke J; Hofmann I; Renkhoff K; Joy S; Vaskelyte L; Sievert H
Catheter Cardiovasc Interv; 2015 Jun; 85(7):1262-7. PubMed ID: 24948394
[TBL] [Abstract][Full Text] [Related]
9. Percutaneous patent foramen ovale closure using the Occlutech Figulla device: More than 1,300 patient-years of follow up.
Snijder RJR; Renes LE; Suttorp MJ; Ten Berg JM; Post MC
Catheter Cardiovasc Interv; 2019 May; 93(6):1080-1084. PubMed ID: 30461175
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous closure of the patent foramen ovale using the HELEX® Septal Occluder: acute and long-term results in 405 patients.
Heinisch C; Bertog S; Wunderlich N; Majunke N; Baranowski A; Leetz M; Fischer E; Staubach S; Zimmermann W; Hofmann I; Sievert H
EuroIntervention; 2012 Oct; 8(6):717-23. PubMed ID: 23086790
[TBL] [Abstract][Full Text] [Related]
11. Long-term experience and outcomes with transcatheter closure of patent foramen ovale.
Inglessis I; Elmariah S; Rengifo-Moreno PA; Margey R; O'Callaghan C; Cruz-Gonzalez I; Baron S; Mehrotra P; Tan TC; Hung J; Demirjian ZN; Buonanno FS; Ning M; Silverman SB; Cubeddu RJ; Pomerantsev E; Schainfeld RM; Dec GW; Palacios IF
JACC Cardiovasc Interv; 2013 Nov; 6(11):1176-83. PubMed ID: 24262618
[TBL] [Abstract][Full Text] [Related]
12. Figulla PFO occluder versus Amplatzer PFO occluder for percutaneous closure of patent foramen ovale.
Saguner AM; Wahl A; Praz F; de Marchi SF; Mattle HP; Cook S; Windecker S; Meier B
Catheter Cardiovasc Interv; 2011 Apr; 77(5):709-14. PubMed ID: 20931665
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous patent foramen ovale closure: outcomes with the Premere and Amplatzer devices.
Bissessor N; Wong AW; Hourigan LA; Jayasinghe RS; Scalia GS; Burstow DJ; Griffiths LR; Savage M; Walters DL
Cardiovasc Revasc Med; 2011; 12(3):164-169. PubMed ID: 21640934
[TBL] [Abstract][Full Text] [Related]
14. Post-Market Clinical Follow-Up With the Patent Foramen Ovale Closure Device IrisFIT (Lifetech) in Patients With Stroke, Transient Ischemic Attack, or Other Thromboembolic Events.
Sievert K; Yu J; Bertog S; Hornung M; von Bardeleben RS; Gafoor S; Reinartz M; Matic P; Hofmann I; Grunwald I; Schnelle N; Sievert H
Cardiovasc Revasc Med; 2021 Sep; 30():72-75. PubMed ID: 33097460
[TBL] [Abstract][Full Text] [Related]
15. Residual Shunt after Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke: Serial Bubble Contrast Transesophageal Echocardiography Data.
Moon J; Kim M; Oh PC; Shin DH; Park HM; Jo YY; Lee JS; Kang WC
J Stroke Cerebrovasc Dis; 2019 Feb; 28(2):347-353. PubMed ID: 30396838
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of different devices for transcatheter closure of patent foramen ovale assessed by serial transoesophageal echocardiography and rates of recurrent cerebrovascular events in a long-term follow-up.
Luani B; Markovic S; Krumsdorf U; Rottbauer W; Wöhrle J
EuroIntervention; 2015 May; 11(1):85-91. PubMed ID: 25572024
[TBL] [Abstract][Full Text] [Related]
17. Comparison of residual shunt rate and complications across 6 different closure devices for patent foramen ovale.
Gevorgyan Fleming R; Kumar P; West B; Noureddin N; Rusheen J; Aboulhosn J; Tobis JM
Catheter Cardiovasc Interv; 2020 Feb; 95(3):365-372. PubMed ID: 31654558
[TBL] [Abstract][Full Text] [Related]
18. Determinants and clinical significance of persistent residual shunting in patients with percutaneous patent foramen ovale closure devices.
Shafi NA; McKay RG; Kiernan FJ; Silverman IE; Ahlquist M; Silverman DI
Int J Cardiol; 2009 Nov; 137(3):314-6. PubMed ID: 19616327
[TBL] [Abstract][Full Text] [Related]
19. Residual Shunt After Patent Foramen Ovale Closure and Long-Term Stroke Recurrence: A Prospective Cohort Study.
Deng W; Yin S; McMullin D; Inglessis-Azuaje I; Elmariah S; Hung J; Lo EH; Palacios IF; Buonanno FS; Ning M
Ann Intern Med; 2020 Jun; 172(11):717-725. PubMed ID: 32422058
[TBL] [Abstract][Full Text] [Related]
20. Interventional closure of patent foramen ovale with Nit-occlud® device in prevention of recurrent neurologic events-Long-term results.
Araszkiewicz A; Sławek S; Trojnarska O; Lesiak M; Grygier M
Catheter Cardiovasc Interv; 2018 Jul; 92(1):159-164. PubMed ID: 29068141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
